This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") | MicrobiomeTrials
← Back to trials NCT07649304
AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-09-11Est. Completion: 2028-04-30
Enrollment target: 15 participantsOther microbiome trials you might be interested in Plasmablastic Lymphoma Ann Arbor Stage I Diffuse Large B-Cell Lymphoma Ann Arbor Stage II Diffuse Large B-Cell Lymphoma Ann Arbor Stage III Diffuse Large B-Cell Lymphoma Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
This feasibility trial studies how well daratumumab in combination with dose-adjusted etoposide, prednisone, vincristine…
Miami, United States Est. completion Jul 2029
Anal Carcinoma Hematopoietic and Lymphoid Cell Neoplasm HIV Infection
Kaposi Sarcoma
Lymphoma
Malignant Solid Neoplasm
Multicentric Castleman Disease
Plasmablastic Lymphoma
Recurrent Kaposi Sarcoma
Recurrent Lymphoma
Recurrent Plasmablastic Lymphoma
Transplant-Related Kaposi Sarcoma
This study collects blood and tissue samples for research of human immunodeficiency virus (HIV)/acquired immunodeficienc…
La Jolla, United States Est. completion Aug 31, 2030